Study Description
This is a multicenter, open label, non-comparative, single arm multi-country study in
approximately 300 adult and pediatric subjects (≥ 6 years of age) with fascioliasis. The
study population consists of male and female adult and pediatric patients (≥ 6 years of
age). The study will enroll approximately 300 subjects with acute (minimum 15% of overall
study population) or chronic fascioliasis. Enrolled subjects will receive two doses of 10
mg/kg of Egaten given approximately 12 hours apart. Subjects will be treated and followed
up on an outpatient basis. After screening and post treatment, at Day 3 and Day 6 the
subjects will be followed for safety and tolerability. These visits are primarily for
safety follow up and may be telephonic or home visit by qualified personnel or onsite
visits based on the investigator's discretion. During visits Day 10, Day 30, Day 60 and
Day 90 post-treatment, the subjects will be followed for safety, tolerability and
efficacy. On Day 15, Day 45 and Day 75, telephonic follow-up (primarily for safety) will
be conducted.
Interventions
Egaten (Triclabendazole) 250 mg tablets
Eligibility Criteria
Inclusion Criteria:
1. Written informed consent must be obtained before any study protocol specific
assessment is performed.
1. Parental/legal guardian informed consent must be obtained and signed for
pediatric subjects (formally documented and witnessed, via an independent
trusted witness) prior to any study related procedure.
2. Subjects < 18 years old, who are capable of providing assent, must provide
assent with parental/legal guardian consent or as per local ethical guidelines.
3. If the subject is unable to read and write or otherwise incapable of signing an
informed consent, then a witnessed consent according to local ethical standards
is permitted.
2. Subjects (Adult and pediatric subjects ≥ 6 years of age and above 12.5 kg of weight)
at time of consenting must have been diagnosed with fascioliasis based on clinical
signs, symptoms and laboratory evaluations as per local clinical practice.
Exclusion Criteria:
1. Subjects diagnosed with ectopic fascioliasis, extrahepatic involvement (e.g., lungs,
spleen, pancreas, subcutaneous tissue, gastrointestinal organs, etc.).
2. Subjects with known hypersensitivity to triclabendazole /other benzimidazole
derivatives and/or any of the excipients in Egaten.
3. Subjects taking any anthelmintic medications within two weeks or 5 half-lives,
whichever is longer prior to enrolling into study.
4. Inability or unwillingness to undergo study related procedures.
5. Subjects who in the judgment of the Clinical Investigator are unsuitable for the
trial or who have to be excluded in order to be compliant with local fascioliasis
management guidelines that may differ from the FDA approved label, including but not
limited to :
1. Subjects who are machine operators or drivers.
2. Medical history of liver (other than fascioliasis), kidney or cardiac disease.
6. Females (including under the age of 18) known to be pregnant or testing positive for
pregnancy at screening.
7. Lactating women unwilling to discontinue lactation up to 72 hours after the second
dose administration or as per local guidelines.
8. Subjects requiring therapeutic drug monitoring of CYP2C19 substrate(s) (e.g.
S-mephenytoin).
9. Subjects with medical history of QT prolongation or a history of symptoms compatible
with a long QT interval or on medication which prolong the QT interval.
Worldwide Contacts
If the location of your choosing does not feature any contact detail, please reach out using the information below.